AN2 Therapeutics, Inc.
NASDAQ:ANTX
1.255 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net Income
| -64.732 | -40.956 | -21.543 | -13.603 | -5.635 |
| Depreciation & Amortization
| 0 | -0.692 | 0 | 0 | 0 |
| Deferred Income Tax
| 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 8.412 | 4.391 | 0.974 | 0.04 | 0 |
| Change In Working Capital
| 5.834 | 3.718 | 0.032 | 1.224 | -0.01 |
| Accounts Receivables
| 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 0.553 | 2.497 | 0.417 | 0.081 | -0.016 |
| Other Working Capital
| 5.281 | 1.221 | -0.385 | 1.143 | 0.006 |
| Other Non Cash Items
| -2.802 | 0.077 | 0.053 | 6.975 | 3.175 |
| Operating Cash Flow
| -53.288 | -33.462 | -20.484 | -5.364 | -2.486 |
| Investing Activities: | |||||
| Investments In Property Plant And Equipment
| 0 | 0 | 0 | 0 | 0 |
| Acquisitions Net
| 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -132.178 | -93.836 | -77.274 | 0 | 0 |
| Sales Maturities Of Investments
| 88.9 | 72.065 | 27.25 | 0 | 0 |
| Other Investing Activites
| 0 | -0.022 | -0.05 | 0 | 0 |
| Investing Cash Flow
| -43.278 | -21.771 | -50.024 | 0 | 0 |
| Financing Activities: | |||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued
| 84.529 | 70.366 | 78.535 | 3.836 | 8.084 |
| Common Stock Repurchased
| 0 | -0.011 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 0.465 | -0.011 | 78.535 | 3.836 | 48.504 |
| Financing Cash Flow
| 84.994 | 70.355 | 78.535 | 3.836 | 8.084 |
| Other Information: | |||||
| Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| -11.572 | 15.122 | 8.027 | -1.528 | 5.598 |
| Cash At End Of Period
| 15.647 | 27.219 | 12.097 | 4.07 | 5.598 |